BR112015018121A2 - composição para terapia por inalação, composição farmacêutica, inalador de pó seco, inalador pressurizado dosimetrado ou inalador nasal ativado por respiração, método de tratar uma doença ou distúrbio respiratório ou uma doença ou distúrbio pulmonar em um paciente, e, método de preparar composições ou inaladores - Google Patents

composição para terapia por inalação, composição farmacêutica, inalador de pó seco, inalador pressurizado dosimetrado ou inalador nasal ativado por respiração, método de tratar uma doença ou distúrbio respiratório ou uma doença ou distúrbio pulmonar em um paciente, e, método de preparar composições ou inaladores

Info

Publication number
BR112015018121A2
BR112015018121A2 BR112015018121A BR112015018121A BR112015018121A2 BR 112015018121 A2 BR112015018121 A2 BR 112015018121A2 BR 112015018121 A BR112015018121 A BR 112015018121A BR 112015018121 A BR112015018121 A BR 112015018121A BR 112015018121 A2 BR112015018121 A2 BR 112015018121A2
Authority
BR
Brazil
Prior art keywords
disorder
inhaler
inhalers
breath
patient
Prior art date
Application number
BR112015018121A
Other languages
English (en)
Inventor
John Burns
Dipesh Parikh
Original Assignee
Prosonix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201301723A external-priority patent/GB201301723D0/en
Priority claimed from GB201310496A external-priority patent/GB201310496D0/en
Application filed by Prosonix Ltd filed Critical Prosonix Ltd
Publication of BR112015018121A2 publication Critical patent/BR112015018121A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112015018121A 2013-01-31 2014-01-29 composição para terapia por inalação, composição farmacêutica, inalador de pó seco, inalador pressurizado dosimetrado ou inalador nasal ativado por respiração, método de tratar uma doença ou distúrbio respiratório ou uma doença ou distúrbio pulmonar em um paciente, e, método de preparar composições ou inaladores BR112015018121A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201301723A GB201301723D0 (en) 2013-01-31 2013-01-31 Pharmaceutical combinations
GB201310496A GB201310496D0 (en) 2013-06-13 2013-06-13 Pharmaceutical combinations
PCT/GB2014/050233 WO2014118532A1 (en) 2013-01-31 2014-01-29 Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy

Publications (1)

Publication Number Publication Date
BR112015018121A2 true BR112015018121A2 (pt) 2017-07-18

Family

ID=50064725

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015018121A BR112015018121A2 (pt) 2013-01-31 2014-01-29 composição para terapia por inalação, composição farmacêutica, inalador de pó seco, inalador pressurizado dosimetrado ou inalador nasal ativado por respiração, método de tratar uma doença ou distúrbio respiratório ou uma doença ou distúrbio pulmonar em um paciente, e, método de preparar composições ou inaladores

Country Status (13)

Country Link
US (1) US9682038B2 (pt)
EP (1) EP2950792A1 (pt)
JP (1) JP2016506947A (pt)
CN (1) CN104955448A (pt)
AU (1) AU2014210942A1 (pt)
BR (1) BR112015018121A2 (pt)
CA (1) CA2898682A1 (pt)
EA (1) EA201591415A1 (pt)
HK (1) HK1215545A1 (pt)
MX (1) MX2015009891A (pt)
SG (1) SG11201505556VA (pt)
WO (1) WO2014118532A1 (pt)
ZA (1) ZA201505258B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201301721D0 (en) * 2013-01-31 2013-03-20 Prosonix Ltd Pharmaceutical Preparations
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
GB201520862D0 (en) * 2015-11-25 2016-01-13 Jagotec Ag Pharmaceutical composition
WO2019060595A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
CN108721219A (zh) * 2017-11-15 2018-11-02 沈阳药科大学 一种生物粘附性肺吸纳米复合微粒及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0201400D0 (en) 2002-01-22 2002-03-13 Glaxo Group Ltd Novel apparatus and process
US7754242B2 (en) * 2002-03-20 2010-07-13 Alkermes, Inc. Inhalable sustained therapeutic formulations
GB0610090D0 (en) 2006-05-20 2006-06-28 Price Robert Particulate drug compositions and their uses
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
GB0705159D0 (en) 2007-03-19 2007-04-25 Prosonix Ltd Process for making crystals
EP3090792A1 (en) 2008-07-18 2016-11-09 Prosonix Limited Process for improving crystallinity
WO2010097188A1 (en) * 2009-02-25 2010-09-02 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a salt of carmoterol and a corticosteroid
EP3106149B1 (en) * 2009-05-29 2019-11-20 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting beta-2 adrenergic receptor agonists and associated methods and systems
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
GB0918431D0 (en) 2009-10-21 2009-12-09 Prosonix Ltd Process for improving crystallinity
JOP20120023B1 (ar) * 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
EP2709447A4 (en) 2011-05-17 2014-10-22 Pearl Therapeutics Inc COMPOSITIONS, METHODS AND SYSTEMS FOR RESPIRATORY ADMINISTRATION OF AT LEAST TWO ACTIVE AGENTS
GB201113662D0 (en) 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
US9452139B2 (en) * 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug

Also Published As

Publication number Publication date
US9682038B2 (en) 2017-06-20
AU2014210942A1 (en) 2015-08-20
EP2950792A1 (en) 2015-12-09
CA2898682A1 (en) 2014-08-07
HK1215545A1 (zh) 2016-09-02
ZA201505258B (en) 2016-12-21
JP2016506947A (ja) 2016-03-07
SG11201505556VA (en) 2015-08-28
US20150366804A1 (en) 2015-12-24
CN104955448A (zh) 2015-09-30
MX2015009891A (es) 2016-03-08
WO2014118532A1 (en) 2014-08-07
EA201591415A1 (ru) 2016-01-29

Similar Documents

Publication Publication Date Title
BR112015018121A2 (pt) composição para terapia por inalação, composição farmacêutica, inalador de pó seco, inalador pressurizado dosimetrado ou inalador nasal ativado por respiração, método de tratar uma doença ou distúrbio respiratório ou uma doença ou distúrbio pulmonar em um paciente, e, método de preparar composições ou inaladores
BRPI1011508A2 (pt) composição farmacêutica, métodos para tratar uma doença ou distúrbio pulmonar em um paciente ou população de pacientes, e para dispensação respiratória de um agente ativo a um paciente, e, inalador de dose medida.
CY1120605T1 (el) Παρασκευασμα ξηρης σκονης που περιλαμβανει εναν αναστολεα φωσφοδιεστερασης
BR112016022598A8 (pt) composição aerossol farmacêutica na forma de um pó seco para liberação pulmonar, forma de dosagem unitária, pacote farmacêutico, kit e uso
BR112013029202A2 (pt) solução farmacêutica, recipiente selado, inalador de dose medida, método para tratar um paciente que sofre ou que está susceptível a sofrer de um distúrbio respiratório, usos de um propelente, de uma composição farmacêutica, e, de um aparelho de administração de medicamentos que contém uma composição farmacêutica
CL2009000601A1 (es) Composicion farmaceutica inhalable en forma de polvo seco que comprende bromuro de aclidinio y un vehiculo, que proporciona una dosis nominal medida de aclinio equivalente a aproximadamente 200 ug de bromuro de aclinio; su uso en epoc y asma; dispositivo inhalador de polvo seco multidosis.
BRPI0905775A2 (pt) composição farmacêutica para inalação, método de tratar uma condição respiratória, uso de aclidínio, aclidínio, formulação e dispositivo inalador
BR112015018120A2 (pt) partículas cristalinas multicomponentes para terapia por inalação, composição farmacêutica, inalador de pó seco, inalador pressurizado dosimetrado, métodos de tratamento de uma doença ou distúrbio respiratório ou uma doença ou distúrbio pulmonar em um paciente, e, de preparação das partículas
NI201400139A (es) Nueva forma de dosificación y formulación de abediterol
TR201109804A2 (tr) Tek dozlu inhalasyon cihazı.
BR112017020039A2 (pt) composição farmacêutica, kit, método, processo para preparar uma composição e solução farmacêutica
MX2022009231A (es) Inhalador de polvo seco y metodo de uso.
CL2013003497A1 (es) Producto farmacéutico de combinación en forma de polvo seco para administración por medio de un inhalador que comprende una sal de umeclidinio de un grupo definido y 100 mcg/dosis de furoato de fluticasona, sin otros activos adicionales; uso para el tratamiento de enfermedades inflamatorias o del aparato respiratorio.
MD20140131A2 (ro) Doză şi formă preparativă nouă pentru inhalare care cuprinde aclidiniu
EA201201391A1 (ru) Ингалятор
CY1117596T1 (el) Φαρμακευτικeς συνθeσεις αερολyματος φορμοτερολης και διπροπιονικης βεκλομεθαζονης
EA201201393A1 (ru) Ингалятор, разработанный для доставки лекарственного средства в виде сухого порошка
EA201201390A1 (ru) Кнопочное устройство мундштука ингалятора сухого порошка
TR201002877A2 (tr) Blister ambalaj içeren inhalasyon cihazı
UA115989C2 (uk) Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії
SG2014011597A (en) Method for preparing metered dose sprayed inhaler for treating respiratory disease
EA201201389A1 (ru) Ингалятор, создающий турбулентность
WO2011037549A3 (en) Dry powder formulation of tiotropium carried in blister strip
EA201201394A1 (ru) Ингалятор для доставки лекарственного средства в виде сухого порошка
DK4188491T3 (da) Inhalator til tørpulverlægemiddel

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2447 DE 28-11-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.